ITGA7: A Potential Drug Target and Biomarker (G3679)

Target Name: ITGA7

NCBI ID: G3679

ITGA7: A Potential Drug Target and Biomarker

Integrin subunit alpha 7 (ITGA7) is a protein that is expressed in various tissues and cell types in the human body. Its function is crucial in the development and maintenance of tissues, including blood vessels, bone marrow, and the nervous system. Unfortunately, ITGA7 has also been implicated in the development of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. As a result, ITGA7 has emerged as a promising drug target and biomarker for a variety of diseases.

Disease-Related Function of ITGA7

The functions of ITGA7 have been extensively studied, and its role in various diseases has been well-described. One of the most well-established functions of ITGA7 is its role in the development and maintenance of blood vessels. ITGA7 is a critical component of the intercellular junctions, which are the junctions between adjacent cells that form the blood vessels. As a result, ITGA7 plays a crucial role in the formation and maintenance of blood vessels, which are essential for delivering oxygen and nutrients to tissues and organs.

In addition to its role in blood vessels, ITGA7 has also been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, studies have shown that ITGA7 is often overexpressed in various diseases, including neurobladder cancer, neurofibromatosis, and multiple sclerosis. Additionally, ITGA7 has been shown to play a role in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Potential Drug Target

The potential drug target for ITGA7 is based on its role in the development and maintenance of blood vessels and its involvement in various diseases. Drugs that target ITGA7 have the potential to treat a variety of conditions, including cancer, neurodegenerative disorders, and autoimmune diseases.

One approach to targeting ITGA7 is to use small molecules that can modulate its activity. For example, inhibitors of ITGA7 have been shown to have potential in treating various diseases, including cancer and neurodegenerative disorders. These inhibitors can disrupt the interaction between ITGA7 and its downstream targets, leading to the inhibition of its activity.

Another approach to targeting ITGA7 is to use antibodies that can specifically recognize and target it. These antibodies can be used to treat diseases that are associated with ITGA7 overexpression, such as cancer, neurodegenerative disorders, and autoimmune diseases.

Biomarker

ITGA7 has also been shown to be a potential biomarker for various diseases. The expression of ITGA7 has been shown to be elevated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Additionally, studies have shown that ITGA7 has been associated with the development of certain diseases, such as neurobladder cancer and neurofibromatosis.

Conclusion

In conclusion, ITGA7 is a protein that is involved in the development and maintenance of various tissues and cells in the human body. Its functions have been extensively studied, and its role in the development and progression of various diseases has been well-described. As a result, ITGA7 has emerged as a promising drug target and biomarker for a variety of diseases. The potential of ITGA7 as a drug target and biomarker is expected to continue to grow as research into its functions and potential therapeutic uses continues.

Protein Name: Integrin Subunit Alpha 7

Functions: Integrin alpha-7/beta-1 is the primary laminin receptor on skeletal myoblasts and adult myofibers. During myogenic differentiation, it may induce changes in the shape and mobility of myoblasts, and facilitate their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity. Isoform Alpha-7X2B and isoform Alpha-7X1B promote myoblast migration on laminin 1 and laminin 2/4, but isoform Alpha-7X1B is less active on laminin 1 (In vitro). Acts as Schwann cell receptor for laminin-2. Acts as a receptor of COMP and mediates its effect on vascular smooth muscle cells (VSMCs) maturation (By similarity). Required to promote contractile phenotype acquisition in differentiated airway smooth muscle (ASM) cells

More Common Targets